IP Library › Granted Patent US 12,571,020
Granted Patent B2
US 12,571,020 · App. 17/801,671 · Granted Mar 10, 2026

Genetically engineered microorganisms that overexpress microcin-mge and methods of purification and use

Inventors: Vanni Bucci (Concord, MA); Benedikt M. Mortzfeld (Newton, MA); Jacob Palmer (Oxford, GB)
Assignee: University of Massachusetts
C12P21/02A61P31/04C07K14/245C12N1/20C12N15/70A61K38/00C12N2510/00C12N2800/101
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,571,020
App. No.
17/801,671
Granted
Mar 10, 2026
Kind
B2
Abstract

This disclosure relates to genetically engineered microorganisms for overexpressing microcin compositions, e.g., MccH47 compositions and MccI47 compositions, which are post-translationally modified with a covalent linkage at the C-terminus to a siderophore, such as mono-glycosylated cyclic enterobactin (MGE), to form microcin-MGE compositions, e.g., MccH47-MGE and MccI47-MGE compositions, the purified compositions themselves, methods of making the purified compositions, and methods of using the purified compositions to treat or reduce the risk of bacterial infections or dysbiosis.

Claims (14)

1 . An isolated and purified microcin-mono-glycosylated cyclic enterobactin (microcin-MGE) composition comprising a class IIb microcin covalently linked at the C-terminus via a single glycosyl molecule to a cyclic enterobactin.

2 . The composition of claim 1 , wherein the microcin-MGE composition comprises an MccH47-MGE, MccI47-MGE, MccE492-MGE, MccM-MGE, or MccG492-MGE composition.

3 . The composition of claim 1 , wherein the microcin-MGE composition comprises an MccH47-MGE composition or an MccI47-MGE composition.

4 . The composition of claim 1 , further comprising a pharmaceutically acceptable carrier comprising one or more of a solvent, dispersion media, coating, antibacterial agent, isotonic and absorption delaying agent, buffer, excipient, binder, lubricant, gel, or a surfactant.

5 . A method of treating a subject for intestinal dysbiosis or a bacterial infection, the method comprising:

identifying a subject as having intestinal dysbiosis or a bacterial infection; and

administering to the subject a therapeutically effective amount of a microcin-MGE composition of claim 1 .

6 . The method of claim 5 , wherein the subject is a human and the composition is administered by endoscopy, enteroscopy, colonoscopy, a nasoduodenal catheter, enema, or orally.

7 . The method of claim 5 , wherein the bacterial infection is a gram-negative bacterial infection.

8 . The method of claim 7 , wherein the bacterial infection is carbapenem-resistant Enterobacteriaceae infection, Campylobacter infection, E. coli infection, Salmonella infection, Shigella infection and/or Yersinia infection.

9 . A method of reducing a risk of a bacterial infection, the method comprising:

identifying a subject as having a risk of a bacterial infection; and

administering to the subject a prophylactically effective amount of a microcin-MGE composition of claim 1 .

10 . The method of claim 9 , wherein the subject is a human and is administered one or more antibiotics.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2022
From: BUCCI, VANNI; MORTZFELD, BENEDIKT; PALMER, JACOB
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 061066/0777 →
Continuity (2)
Provisional Application 62980921 · Feb 24, 2020
Related Publication 20230126514A1 · Apr 27, 2023
References Cited (58)
US 11560543B2 · Bucci et al. · 2023 [cited by applicant]
US 20060269988A1 · Royer et al. · 2006 [cited by applicant]
US 20150209393A1 · Wook et al. · 2015 [cited by applicant]
US 20200270569A1 · Bucci et al. · 2020 [cited by applicant]
US 20220218787A1 · Bucci et al. · 2022 [cited by applicant]
WO WO2010025267 · 2010 [cited by applicant]
WO WO2016072936 · 2016 [cited by applicant]
WO WO2016210373 · 2016 [cited by applicant]
WO WO2018237198 · 2018 [cited by applicant]
WO WO2019055781 · 2019 [cited by applicant]
Palmer et al., “Microcin H47: A Class IIb Microcin with Potent Activity Against Multidrug Resistant Enterobacteriaceae”, ACS Infect. Dis. 6:672-679, 2020 (Year: 2020). [cited by examiner]
Vassiliadis G, Destoumieux-Garzón DLombard C, Rebuffat S, Peduzzi J. (2010). Isolation and Characterization of Two Members of the Siderophore-Microcin Family, Microcins M and H47. Antimicrob Agents Chemother 54, No. 1. [cited by examiner]
Thomas et al. (The Journal of Biological Chemistry. Vol. 279, No. 27, Issue of Jul. 2, 2004; pp. 28233-28242). [cited by examiner]
Azpiroz et al., “Microcin H47 system: an [cited by applicant]
Azpiroz et al., “Microcins and urovirulence in [cited by applicant]
Bayro et al., “Structure of antibacterial peptide microcin J25: a 21-residue lariat protoknot,” Journal of the American Chemical Society, Oct. 13, 2003, 125(41):12382-3. [cited by applicant]
Bucci et al., “The evolution of bacteriocin production in bacterial biofilms,” The American Naturalist, Dec. 1, 2011, 178(6):E162-73. [cited by applicant]
Chatham-Stephens et al., “Emergence of extensively drug-resistant [cited by applicant]
Daeffler et al., “Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation,” Molecular Systems Biology, Apr. 2017, 13(4):923, 13 pages. [cited by applicant]
David et al., “Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread,” Nature Microbiology, Nov. 2019, 4(11):1919-29. [cited by applicant]
Delgado et al., “YojI of [cited by applicant]
Duquesne et al., “Microcins, gene-encoded antibacterial peptides from enterobacteria,” Natural Product Reports, 2007, 24(4):708-34. [cited by applicant]
EP European Search Report in European Appln. No. 18856596.4, dated Aug. 7, 2020, 17 pages. [cited by applicant]
EP European Search Report in European Appln. No. 20802507.2, dated Jun. 15, 2022, 9 pages. [cited by applicant]
EP Extended European Search Report in European Appln. No. 18856596.4, dated Nov. 10, 2020, 15 pages. [cited by applicant]
Fomenko et al., “Regulation of microcin C51 operon expression: the role of global regulators of transcription,” Research in Microbiology, Jun. 1, 2001, 152(5):469-79. [cited by applicant]
Geldart et al., “pMPES: a modular peptide expression system for the delivery of antimicrobial peptides to the site of gastrointestinal infections using probiotics,” Pharmaceuticals, Dec. 2016, 9(4):60, 16 pages. [cited by applicant]
Geldart et al., “pMPES: a modular peptide expression system for the delivery of antimicrobial peptides to the site of gastrointestinal infections using probiotics,” Pharmaceuticals, Oct. 2, 2016, 9(4):60, 16 pages. [cited by applicant]
Gibson et al., “Enzymatic assembly of DNA molecules up to several hundred kilobases,” Nature Methods, May 2009, 6(5):343-5. [cited by applicant]
Landry et al., “Engineering diagnostic and therapeutic gut bacteria,” Microbiology Spectrum, Oct. 2017, 5(5), 22 pages. [cited by applicant]
Medina et al., “Tackling threats and future problems of multidrug-resistant bacteria,” How to Overcome the Antibiotic Crisis, 2016, 3-33. [cited by applicant]
Mercado et al., “The production in vivo of microcin E492 with antibacterial activity depends on salmochelin and EntF,” Journal of Bacteriology, Aug. 1, 2008, 190(15):5464-71. [cited by applicant]
Metelev et al., “Structure of microcin B-like compounds produced by Pseudomonas syringae and species specificity of their antibacterial action, ” Journal of Bacteriology, Sep. 15, 2013, 195(18):4129-37. [cited by applicant]
Mortzfeld et al., “MccI47 selectively inhibits enteric bacteria and reduces carbapenem-resistant Klebsiella pneumoniae colonization in vivo when administered via an engineered live biotherapeutic,” bioRxiv, Jan. 1, 2021… [cited by applicant]
Nadell et al., “Cutting through the complexity of cell collectives. Proceedings of the Royal Society B: Biological Sciences,” Mar. 22, 2013, 280, 11 pages. [cited by applicant]
Ng et al., “Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens,” Nature, Oct. 2013, 502(7469):96-9. [cited by applicant]
Nolan et al., “Biosynthetic tailoring of microcin E492m: post-translational modification affords an antibacterial siderophore-peptide conjugate,” Journal of the American Chemical Society, Nov. 21, 2007, 129(46):14336-47. [cited by applicant]
Nolan et al., “Investigations of the MceIJ-catalyzed posttranslational modification of the microcin E492 C-terminus: linkage of ribosomal and nonribosomal peptides to form “trojan horse” antibiotics,” Biochemistry, Sep.… [cited by applicant]
Palmer et al., “Engineered probiotic for the inhibition of Salmonella via tetrathionate-induced production of microcin H47,” ACS Infectious Diseases, Jan. 12, 2018, 4(1):39-45. [cited by applicant]
Patzer et al., “The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN,” Microbiology, Sep. 1, 2003, 149(9):2557-70. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2018/051079, dated Mar. 17, 2020, 9 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2020/031182, dated Nov. 2, 2021, 6 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2021/019225, dated Feb. 3, 2022, 11 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/U20S18/051079 dated Feb. 7, 2019, 13 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/031182, dated Aug. 18, 2020, 9 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2021/019225, dated Aug. 10, 2021, 11 pages. [cited by applicant]
Poey et al., “Comparative analysis of chromosome-encoded microcins,” Antimicrobial Agents and Chemotherapy, Apr. 1, 2006, 50(4):1411-8. [cited by applicant]
Poey et al., “Virulence profiles in uropathogenic [cited by applicant]
Riglar et al., “Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation,” Nature Biotechnology, Jul. 2017, 35(7):653-8. [cited by applicant]
Rodríguez et al., “The structural gene for microcin H47 encodes a peptide precursor with antibiotic activity,” Antimicrobial Agents and Chemotherapy, Sep. 1, 1999, 43(9):2176-82. [cited by applicant]
Rojas et al., “Multidrug-Resistant Klebsiella pneumoniae ST307 in Traveler Returning from Puerto Rico to Dominican Republic,” Emerging Infectious Diseases, Aug. 2019, 25(8):1583-5. [cited by applicant]
Sassone-Corsi et al.et al., Microcins Mediate Competition Among Enterobacteriaceae in the Inflamed Gut Naure; Dec. 8, 2016; vol. 540, 25 pages. [cited by applicant]
Vassiliadis et al., “Isolation and characterization of two members of the siderophore-microcin family, microcins M and H47,” Antimicrobial Agents and Chemotherapy, Jan. 2010, 54(1):288-97. [cited by applicant]
Winter et al., “Gut inflammation provides a respiratory electron acceptor for [cited by applicant]
Winter et al., “Host-derived nitrate boosts growth of [cited by applicant]
Bantysh et al., “Enzymatic synthesis of bioinformatically predicted microcin C-like compounds encoded by diverse bacteria,” Mbio, Jul. 2014, 5(3):10, 11 pages. [cited by applicant]
EP Extended European Search Report in European Appln. No. 21760771.2, mailed on Mar. 14, 2024, 11 pages. [cited by applicant]
Gaggero et al., “Genetic analysis of microcin H47 antibiotic system,” Journal of Bacteriology, Sep. 1993, 175(17):5420-7. [cited by applicant]